These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

51 related articles for article (PubMed ID: 1347112)

  • 1. Is ondansetron "too expensive"?
    Pannuti F; Tanneberger S; Lelli G; Piana E
    Lancet; 1992 Mar; 339(8793):614-5. PubMed ID: 1347112
    [No Abstract]   [Full Text] [Related]  

  • 2. 2005 Medicare payments for chemotherapy will exceed costs.
    Zielinski SL
    J Natl Cancer Inst; 2005 Jan; 97(1):7. PubMed ID: 15632370
    [No Abstract]   [Full Text] [Related]  

  • 3. Cost-effectiveness analysis of oral ondansetron and prochlorperazine for preventing nausea and vomiting after moderately emetogenic chemotherapy.
    Kwong WJ; Parasuraman TV
    Pharm Pract Manag Q; 1999 Apr; 19(1):28-41. PubMed ID: 10351607
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic evaluation of ondansetron vs dimenhydrinate for prevention of postoperative vomiting in children undergoing strabismus surgery.
    Piwko C; Lasry A; Alanezi K; Coyte PC; Ungar WJ
    Paediatr Anaesth; 2005 Sep; 15(9):755-61. PubMed ID: 16101706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effective use of antiemetics.
    Grunberg SM
    Oncology (Williston Park); 1998 Mar; 12(3 Suppl 4):38-42. PubMed ID: 9556782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tropisetron, ondansetron, and granisetron for control of chemotherapy-induced emesis in Turkish cancer patients: a comparison of efficacy, side-effect profile, and cost.
    Abali H; Celik I
    Cancer Invest; 2007; 25(3):135-9. PubMed ID: 17530482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Double-blind comparative trial of oral ondansetron versus oral granisetron versus IV ondansetron in the prevention of nausea and vomiting associated with highly emetogenic preparative regimens prior to stem cell transplantation.
    Fox-Geiman MP; Fisher SG; Kiley K; Fletcher-Gonzalez D; Porter N; Stiff P
    Biol Blood Marrow Transplant; 2001; 7(11):596-603. PubMed ID: 11760147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective randomized trial of the antiemetic efficacy and cost-effectiveness of intravenous and orally disintegrating tablet of ondansetron in children with cancer.
    Corapçioglu F; Sarper N
    Pediatr Hematol Oncol; 2005 Mar; 22(2):103-14. PubMed ID: 15804995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmaceutical development of ondansetron injection.
    Leak RE; Woodford JD
    Eur J Cancer Clin Oncol; 1989; 25 Suppl 1():S67-9. PubMed ID: 2533902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ondansetron reduces chemotherapy induced nausea and vomiting refractory to standard antiemetics.
    Mitchell PL; Evans BD; Allan SG; Forgeson GV; Mak D; Neave L; Humm G; Langley G; Dickson D; Harvey VJ
    N Z Med J; 1992 Mar; 105(929):73-5. PubMed ID: 1532054
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Haloperidol for postoperative nausea and vomiting: are we reinventing the wheel?
    Habib AS; Gan TJ
    Anesth Analg; 2008 May; 106(5):1343-5. PubMed ID: 18420842
    [No Abstract]   [Full Text] [Related]  

  • 12. Cost-effectiveness as a guide to pricing a new pharmaceutical product.
    Reekie WD; Buxton MJ
    S Afr Med J; 1994 Jul; 84(7):421-3. PubMed ID: 7709308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Are drugs too expensive in Canada? Yes.
    Lexchin J
    Can Fam Physician; 2006 May; 52(5):573-6, 578-81. PubMed ID: 16739821
    [No Abstract]   [Full Text] [Related]  

  • 14. Proceedings of the Ondansetron Symposium. London, 30 June 1989.
    Eur J Cancer Clin Oncol; 1989; 25 Suppl 1():S1-93. PubMed ID: 2533893
    [No Abstract]   [Full Text] [Related]  

  • 15. Nurses' perceptions of antiemetic effectiveness.
    Rhodes VA; McDaniel RW; Simms SG; Johnson M
    Oncol Nurs Forum; 1995 Sep; 22(8):1243-52. PubMed ID: 8532549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinical pharmacology of ondansetron.
    Blackwell CP; Harding SM
    Eur J Cancer Clin Oncol; 1989; 25 Suppl 1():S21-4; discussion S25-7. PubMed ID: 2533895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Are drug too expensive in Canada? No.
    Williams R; Marion J
    Can Fam Physician; 2006 May; 52():573-6, 578-81. PubMed ID: 16739822
    [No Abstract]   [Full Text] [Related]  

  • 18. Ondansetron, important new antiemetic, approved by FDA.
    Oncology (Williston Park); 1991 Mar; 5(3):12. PubMed ID: 1829939
    [No Abstract]   [Full Text] [Related]  

  • 19. Three reports at ASCO show ondansetron to be a very effective antiemetic with few side effects.
    Oncology (Williston Park); 1990 Sep; 4(9):98, 102. PubMed ID: 2145023
    [No Abstract]   [Full Text] [Related]  

  • 20. Safety of ondansetron.
    Smith RN
    Eur J Cancer Clin Oncol; 1989; 25 Suppl 1():S47-50; discussion S51-4. PubMed ID: 2533899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.